乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

ACC

<乌鸦传媒>Wegovy Helps HFpEF Patients With Diabetes Mellitus

Weight and symptoms improved in STEP-HFpEF DM trial

<乌鸦传媒>Proof of Benefit in Acute MI Again Evades an SGLT2 Inhibitor

Yet empagliflozin gets a boost from a lower risk of total HF events in EMPACT-MI

<乌鸦传媒>Cardiology's Bid to Defect From ABIM Plows Ahead

Application to form a new board is in, and it could be operational as soon as 2025

<乌鸦传媒>Interatrial Shunt's Prospects in Heart Failure Shrink After RELIEVE-HF

Ventura device showed promise in narrower pool of HF patients with reduced EF

<乌鸦传媒>ACC Meeting to Make Noise on Beta-Blockers, SGLT2i, Chelation Therapy for Acute MI

Plus an update on the new cardiovascular board at Atlanta meeting

<乌鸦传媒>More Sophisticated Imaging Doesn't Necessarily Mean Better Outcomes in Ischemic HF

But cardiac MRI, PET may still have value in some patients, per AIMI-HF trial

<乌鸦传媒>Adaptive Pacemaker Fails in HFpEF

Improvement in oxygen consumption response to physical exertion not observed in a small trial

<乌鸦传媒>Pulsed Field Afib Ablation Hits Endpoints in Pivotal Trial

Technology appears durable in most patients

<乌鸦传媒>Virtual Care Team Optimized Heart Failure Medications During Hospitalization

Trial shows modest effect with daily recommendations to the treating team

<乌鸦传媒>Statin Users Show LDL Doesn't Come Close to Telling Whole Story of ASCVD

Residual inflammation is important factor of cardiovascular risk

<乌鸦传媒>Elite Athletes With Genetic Heart Disease Can Still Play Ball

With a comprehensive return-to-play protocol, most athletes played again, researchers say

<乌鸦传媒>Full-Dose Anticoagulation Again Favored for COVID Admissions

Despite failures, FREEDOM trial supports mortality advantage in general ward use

<乌鸦传媒>Sotatercept, Fixed-Dose Combo Therapy on the Right Path for PAH

More therapeutic options suggested by STELLAR, A DUE trials

<乌鸦传媒>Thrombectomy Linked to Better High-Risk Pulmonary Embolism Outcomes

Observational study suggests fewer deaths than with other approaches

<乌鸦传媒>TAVR Holds Strong 3 Years Into Evolut Low Risk Trial

No major widening nor narrowing of event curves yet

<乌鸦传媒>No Copay Is No Help for CVD Outcomes

Randomized trial showed a small bump in adherence, but didn't move the dial on outcomes

<乌鸦传媒>Minimally Invasive Mitral Valve Surgery Earns Confidence in Expert Hands

Decision for mini thoracotomy may rest on patient preference, expert operator availability

<乌鸦传媒>Immediate Complete Revascularization Non-Inferior to Staged Procedure

Patients with ACS and multivessel disease saw multiple outcome benefits in BIOVASC trial

<乌鸦传媒>Hunt for Hibernating Myocardium Doesn't Help PCI for Ischemic Cardiomyopathy

REVIVED-BCIS2 challenges long-held beliefs about myocardial viability

<乌鸦传媒>Novel Antihypertensive Stumbles Over Early-Phase Hurdle

Hopes remain high for baxdrostat despite trial's adherence problems

<乌鸦传媒>TEER Improves Quality of Life With Severe Tricuspid Regurgitation

Pivotal trial is first to evaluate "impact of TR reduction on long-term effects on survival"

<乌鸦传媒>Bempedoic Acid Proves Clinical Benefits for the Statin-Intolerant

Yet the good clinical data are complicated by real-world cost and access problems

<乌鸦传媒>Atorvastatin Tied to Cardioprotection for Lymphoma Patients on Anthracyclines

STOP-CA deemed "an impactful study that will lead to more prescription of statins in patients."

<乌鸦传媒>Gender Affirmation Hormones Come With Cardiovascular Tradeoffs

National hospital data add to the literature on HRT's risk-benefit profile

<乌鸦传媒>Anticoagulation Goes Head-to-Head With DAPT After Valve Surgery

Edoxaban not significantly better for thrombosis protection in "underpowered" ADAPT-TAVR trial

<乌鸦传媒>Two PCI Guidance Strategies on Par for Intermediate Coronary Stenosis

FLAVOUR trial weighs in on FFR versus IVUS

<乌鸦传媒>Which Drug-Coated Balloon Proved Superior in Peripheral Artery Disease?

Second-generation device goes head-to-head with popular first-gen device

<乌鸦传媒>Cardiac Monitoring Finds Arrhythmias, but Treatment Did Not Improve Outcomes

No differences in mortality, hospitalization between monitored patients and control patients

<乌鸦传媒>TAVR Valve Outlasts Surgical Bioprostheses at 5 Years

No longer assume that TAVR bioprostheses are inherently less durable

<乌鸦传媒>Study Provides 'Elusive' Link Between Kids' Health and Adult Heart Events

CV risk factors in childhood tied to midlife CV events and CVD

<乌鸦传媒>Patiromer Limits Impact of RAAS Inhibitor-Related Hyperkalemia in HF

Patients better able to achieve target dose of mineralocorticoids and angiotensin inhibitors

<乌鸦传媒>Transcatheter Tricuspid Repair Shows Early Promise

PASCAL device safe and linked to symptom improvement in severe tricuspid regurgitation

<乌鸦传媒>Extra Warming Efforts in Surgery Turn Out to Be Hot Air

PROTECT trial finds targeting body temperatures a few degrees higher is unnecessary

<乌鸦传媒>Flu Vaccine Didn't Stop Vascular Events in Heart Failure Patients

But study in lower income countries sees hint of benefit during peak disease season

<乌鸦传媒>Shoppers Adhered to Heart-Healthy Diet in Novel Program

Researchers teamed with supermarket chain to improve DASH scores

<乌鸦传媒>Don't Wait, Ablate to Prevent VT Episodes After an ICD Shock?

Early catheter ablation reduced deaths and ICD shocks in PARTITA trial

<乌鸦传媒>EHR Pop-Ups Spur Better GDMT Implementation in Heart Failure

Alert-based intervention in PROMPT-HF trial said to be low-cost, scalable

<乌鸦传媒>Higher-Dose ANGPTL3 Inhibitor Cuts Lipids but With Questionable Safety

Significant safety signals in dose-ranging trial may end drug's future in CV prevention

<乌鸦传媒>Add-On Mavacamten Cuts Need for Septal Reduction in Obstructive HCM

VALOR-HCM trial shows novel cardiac myosin inhibitor beneficial as targeted treatment

<乌鸦传媒>Tide Turns on Withholding Blood Pressure Meds for Pregnant Women

Antihypertensive treatment was safe for mothers and children in the CHAP trial

1